PharmGen Science, Inc. (004720.KS)

PharmGen Science, Inc. (004720.KS) — VMCI valuation read

Headline read on 004720.KS: VMCI of 47/100 versus a broad-market sample median of 50. The 3-point below-median position is what makes PharmGen Science, Inc. a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on 004720.KS: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on 004720.KS: value (004720.KS trades at 21.0x earnings, 17% above the sector median of 18.0x), quality (ROIC of 15.0% sits 5.0pp above the sector median (10.0%)), and risk (net debt to EBITDA of 2.7x is the rate-sensitivity line to watch). The value read also implies an EV/EBITDA gap of +4.0x against the sector 12.0x baseline.

004720.KS fell 1.1% over the trailing 7 days, with a -10.6% read on a 30-day basis.